Browse Category

Solutions - Page 21

New Medical Solutions curates credible advances that solve real problems in healthcare—faster diagnosis, safer procedures, better monitoring, smoother coordination, and fairer access.

Lupin rides the onshoring wave, pledging $250M to build new respiratory production plant in Fla.

Lupin expects to invest a combined $250 million—covering R&D, infrastructure and capital expenditures over five years—to build a new pharmaceutical production plant in Coral Springs, Florida. The site will focus on the

October 9, 2025

News·Solutions

OXB kicks off US expansion, buying viral vector plant in N.C. from National Resilience for $4.5M

Less than two months after OXB revealed a plan to expand its operations in the U.S., the U.K.-based cell and gene therapy manufacturer has purchased a viral vector plant in North Carolina

October 7, 2025

News·Solutions

Eli Lilly earmarks $1B-plus for contract manufacturing partnerships in India

The company will work with new local contract manufacturers in India to boost supply of its key medicines.

October 6, 2025

News·Solutions

FDA launches generics pilot program, advances facility PreCheck proposal in bid to incentivize US drug manufacturing

The FDA unveiled a new pilot program that aims to speed up review times for generic drugmakers who test and manufacture their products in the U.S. Separately, the agency met with industry

October 3, 2025

News·Solutions

Cidara snares up to $339M from BARDA to bankroll its non-vaccine flu candidate

The initial part of the up-to-$339 million funding will largely be used to establish U.S. manufacturing for the non-vaccine flu preventive candidate, with additional options tied to further clinical studies, Cidara said.

October 3, 2025

News·Solutions

Vaxcyte strikes up to $1B deal for fill-finish space at Thermo Fisher’s N.C. production facility

Vaxcyte is paying Thermo Fisher Scientific up to $1 billion to access vaccine fill-finish capacity at the CDMO’s production facility in Greenville, North Carolina. Vaxcyte positioned the deal as a “long-term U.S.

October 2, 2025

News·Solutions

Ansa snares $54.4M in series B financing to boost its DNA synthesis platform

Ansa Biotechnologies hauled in a total of $54.4 million in an oversubscribed series B financing round that will be used to expand the company’s DNA synthesis production capacity in the U.S.

October 2, 2025

News·Solutions

Redesigning Healthcare for a Sustainable Tomorrow

In an increasingly complex global healthcare landscape, cross-sector collaboration has become essential to solving the systemic challenges we face in the medical device industry. The future of healthcare will be defined not

August 13, 2025

Solutions

The Hidden Cost of Siloed Hardware and Firmware in MedTech

Medical device innovation is complex by nature, but many of the most persistent problems in product development are avoidable. One of the most common and costly mistakes in terms of both time

August 13, 2025

Solutions

GeniPhys receives FDA clearance for self-assembling collagen scaffold

INDIANAPOLIS – GeniPhys, a medtech innovator specializing in next-generation regenerative collagen polymeric biomaterials, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its flagship product, Collymer Self-Assembling Scaffold (SAS).

July 10, 2025

Solutions

Previous 1 … 19 20 21 22 Next

Go toTop